GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (XCNQ:DRUG) » Definitions » Asset Turnover

Bright Minds Biosciences (XCNQ:DRUG) Asset Turnover : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Bright Minds Biosciences's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Bright Minds Biosciences's Total Assets for the quarter that ended in Dec. 2023 was C$6.88 Mil. Therefore, Bright Minds Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Bright Minds Biosciences's annualized ROE % for the quarter that ended in Dec. 2023 was -106.66%. It is also linked to ROA % through Du Pont Formula. Bright Minds Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 was -97.86%.


Bright Minds Biosciences Asset Turnover Historical Data

The historical data trend for Bright Minds Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Asset Turnover Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Asset Turnover
- - - -

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bright Minds Biosciences's Asset Turnover

For the Biotechnology subindustry, Bright Minds Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Asset Turnover falls into.



Bright Minds Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Bright Minds Biosciences's Asset Turnover for the fiscal year that ended in Sep. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Sep. 2023 )/( (Total Assets (A: Sep. 2022 )+Total Assets (A: Sep. 2023 ))/ count )
=0/( (12.087+6.879)/ 2 )
=0/9.483
=0.00

Bright Minds Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (6.879+6.887)/ 2 )
=0/6.883
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Bright Minds Biosciences  (XCNQ:DRUG) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Bright Minds Biosciences's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-6.736/6.3155
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-6.736 / 0)*(0 / 6.883)*(6.883/ 6.3155)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.0899
=ROA %*Equity Multiplier
=-97.86 %*1.0899
=-106.66 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Bright Minds Biosciences's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-6.736/6.883
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-6.736 / 0)*(0 / 6.883)
=Net Margin %*Asset Turnover
= %*0
=-97.86 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Bright Minds Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences (XCNQ:DRUG) Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Bright Minds Biosciences (XCNQ:DRUG) Headlines